Phytocannabinoids in Triple Negative Breast Cancer Treatment: Current Knowledge and Future Insights


Review

. 2023 Mar;43(3):993-1000.


doi: 10.21873/anticanres.16243.

Affiliations

Item in Clipboard

Review

Sabrina Bimonte et al.


Anticancer Res.


2023 Mar.

Abstract

Triple negative breast cancer (TNBC) represents an aggressive subtype of breast cancer, which is deficient in estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. Thus, TNBC cells are unable to respond to the conventional hormonal therapies, making chemotherapy the only therapeutic choice. Patients with TNBC develop metastasis and recurrence over time and have reduced survival compared to patients with other subtypes of breast cancer. Therefore, there is a need for innovative therapies. Data emerged from pre-clinical studies, highlighted various antitumor activities of plant-derived Cannabis sativa and synthetic cannabinoids (CBs), including delta-9-tetrahydrocannabinol (THC) and non-psychoactive cannabidiol (CBD). On the contrary, some studies indicated that CBs might also promote tumor progression. At present, clinical studies on the effects of CBs from Cannabis sativa in cancer patients are few. In the present study, we reviewed known and possible interactions between cannabinoids and TNBC therapies.


Keywords:

Cannabis sativa; cannabidiol; cannabinoids; delta-9-tetrahydrocannabinol; triple-negative breast cancer.

Read more here: Source link

Leave a Reply

Your email address will not be published. Required fields are marked *